This research was presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), a gathering of over 30,000 oncology professionals in Chicago.
Celestia S. Higano, professor, Medical Oncology Division, University of Washington School of Medicine, discusses an analysis looking at sexual health and pelvic floor physiotherapy services for patients with prostate cancer. This research was presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), a gathering of over 30,000 oncology professionals in Chicago.
Novel Drug Granted FDA Fast Track in Rare Prostate Cancer Subset
February 13th 2024The Food and Drug Administration has granted a Fast Track designation to the novel immune activator drug BXCL701 in combination with a checkpoint inhibitor for patients with metastatic small cell neuroendocrine prostate cancer (SCNC).
Read More